Dr. Ferhina Ali joins the program to discuss the March 2020 issue of Retinal Physician including a discussion of various extended-durability agents currently in trials.
Financial Disclosures: Dr. Sridhar is a consultant for Alcon, Alimera, and Oxurion. Dr. Ali is a Genentech employee and stock holder, and has consulted for Voyant biotherapeutics and Forsight.
CME Information
Release: March 8, 2020; expires March 8, 2023
Reviewers: Purnima Patel, MD; Shriji Patel, MD; Carl Danzig, MD
Disclosures: The physician reviewers and Academy staff report no relevant financial disclosures.
Learning Objective: Upon completion of this episode, the listener should be able to describe evolving standards of care for the management of vitreoretinal disorders or the outcomes from recent research and how these impact patient care decisions.
Audience: This activity is intended for retina subspecialists and comprehensive ophthalmologists.
Accreditation: The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American Academy of Ophthalmology designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits.TM Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hardware/Software Requirements: This learning activity requires a current web browser and speaker or headset capable of playing streaming audio.